RecruitingPhase 2NCT06776250

Study of How Safe and Effective Tarlatamab is in Brain Cancers

Studying Astrocytoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Health Network, Toronto
Principal Investigator
Eric Chen, MD, MD
Princess Margaret Cancer Centre/University Health Network
Intervention
Tarlatamab(drug)
Enrollment
44 enrolled
Eligibility
18 years · All sexes
Timeline
2025 – 2028

Study locations (1)

Collaborators

Amgen

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06776250 on ClinicalTrials.gov

Other trials for Astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Astrocytoma →

← Back to all trials